2-(pyridin-3-yl)-5-(trifluoromethyl)aniline | 158461-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(pyridin-3-yl)-5-(trifluoromethyl)aniline
• 英文别名: 2-pyridin-3-yl-5-(trifluoromethyl)aniline
• CAS: 158461-54-2
• 化学式: C₁₂H₉F₃N₂
• mdl: MFCD15477200
• 分子量: 238.212
• InChiKey: JMJRNKHNVRWDBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(pyridin-3-yl)-5-(trifluoromethyl)aniline 在 溶剂黄146 、 sodium nitrite 、 sodium azide 作用下， 以 水 为溶剂， 反应 1.5h， 以80%的产率得到3-(2-Azido-4-(trifluoromethyl)phenyl)pyridine
  参考文献：
  名称：

  钌催化芳基叠氮化物形成 γ-碳鎓离子；二甲酚的合成

  摘要：

  通过 3-吡啶基取代的芳基叠氮化物的钌 (III) 催化反应，立体选择性地生产一系列 γ-咔啉。其他催化剂和条件既没有那么选择性，也没有那么高产率。该方法用于简洁、高效地合成二甲苯啉。

  DOI：

  10.1021/ol2008268
• 作为产物：
  描述：

  3-(2-nitro-4-(trifluoromethyl)phenyl)pyridine 在 盐酸 、 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以82%的产率得到2-(pyridin-3-yl)-5-(trifluoromethyl)aniline
  参考文献：
  名称：

  二取代苯基吡啶衍生物的合成及抗心律失常活性。

  摘要：

  合成了一系列双取代的苯基吡啶衍生物，并研究了它们对氯仿诱导的小鼠心律失常的抗心律失常作用。其中，2-和3- [2-（3-氨基丁酰胺基）-4-（2,2,2-三氟乙氧基）苯基]嘧啶二烯（23h，24h）和3- [2-（3-氨基丁酰胺基）-4 -乙氧基苯基]吡啶（24i）显示有效的抗心律不齐活性。他们具有美西律（III）效力的大约两倍。从该系列中选择化合物24i作为进一步开发的候选化合物；它被发现具有IB类电生理特性，并显示出心肌中钠通道的慢速依赖于速率的阻滞（RDB）。

  DOI：

  10.1248/cpb.41.1573

文献信息

• [EN] PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS<br/>[FR] ACIDES PHÉNYLSULFAMOYLBENZOÏQUES EN TANT QUE MODULATEURS D'ERAP1
  申请人：GREY WOLF THERAPEUTICS LTD

  公开号：WO2020225569A1

  公开（公告）日：2020-11-12

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally substituted by one ormore substituents selected from alkyl, cycloalkyl, halo, alkoxy, CN, haloalkyl and OH; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, C land alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl,Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl andhaloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl,SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionallysubstituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl and halo; and R9 is H, alkyl or halo; R10 and R11 are each independently H or alkyl; and R12 and R13 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immuno- oncology and related applications. Another aspect of the invention relates to compounds of formulae (la) and (lb).

  本发明涉及一种具有式(I)的化合物，或其药学上可接受的盐或水合物，其中：基团X-Y为-NHSO2-或-SO2NH-；Z为单环芳基或杂环芳基，每个基团可选择地由一种或多种从烷基、环烷基、卤素、烷氧基、CN、卤代烷基和羟基中选择的取代基取代；R1为H或烷基；R2从COOH和四唑基团中选择；R3从H、C和烷基中选择；R4从H和卤素中选择；R5从H、烷基、卤代烷基、SO2-烷基、Cl、烷氧基、OH、CN、羟基烷基、烷基硫、杂环芳基、环烷基、杂环烷基和卤代烷氧基中选择；R6为H；R7从H、CN、卤代烷基、卤素、SO2-烷基、SO2NR12R13、杂环芳基、CONR10R11和烷基中选择，其中所述的杂环芳基可选择地由一种或多种从烷基、卤素、烷氧基、CN、卤代烷基和羟基中选择的取代基取代；R8从H、烷基、卤代烷基和卤素中选择；R9为H、烷基或卤素；R10和R11各自独立地为H或烷基；R12和R13各自独立地为H或烷基。本发明的进一步方面涉及这些化合物在免疫肿瘤学领域及相关应用中的用途。本发明的另一个方面涉及式(la)和(lb)的化合物。
• ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20170240527A1

  公开（公告）日：2017-08-24

  In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.

  为了为Trk相关疾病提供一种预防和/或治疗剂，本发明提供了一种具有选择性Trk抑制活性的化合物，持续抑制NGF血管高渗透性，并且不具有药物相互作用，此外，该化合物在溶解性和对游离碱的吸收性方面表现出色。本发明的化合物具有选择性Trk抑制活性，持续抑制NGF血管高渗透性，不具有药物相互作用，在溶解性和对游离碱的吸收性方面表现出色，因此可作为Trk相关疾病的预防和/或治疗剂。
• Trk-INHIBITING COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20160000783A1

  公开（公告）日：2016-01-07

  The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.

  本发明提供了一种药物，其中包含具有Trk抑制活性的化合物作为预防和/或治疗Trk相关疾病的活性成分，例如疼痛、瘙痒、下尿路功能障碍、哮喘、过敏性鼻炎、炎症性肠病或查加斯病。通式（I）所表示的化合物，其中所有符号都表示规范中描述的相同含义，其盐，N-氧化物，溶剂化物或前药是作为具有Trk抑制活性的药物成分在预防和/或治疗疼痛、瘙痒、下尿路功能障碍、哮喘、过敏性鼻炎、炎症性肠病或查加斯病等疾病中有用的。
• Trk-inhibiting compound
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10300060B2

  公开（公告）日：2019-05-28

  The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.

  本发明提供了一种含有具有Trk-抑制活性的化合物的药物，作为预防和/或治疗Trk相关疾病（如疼痛、瘙痒、下尿路功能障碍、哮喘、过敏性鼻炎、炎症性肠病或南美锥虫病）的活性成分。通式(I)（其中所有符号代表与说明书所述相同的含义）代表的化合物、其盐、其 N-氧化物、其溶解物或其原药可作为具有 Trk 抑制活性的药物成分，用于预防和/或治疗疼痛、瘙痒、下尿路功能障碍、哮喘、过敏性鼻炎、炎症性肠病或南美锥虫病等疾病。
• Acid-addition salt of Trk-inhibiting compound
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10399959B2

  公开（公告）日：2019-09-03

  In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.

  为了提供一种预防和/或治疗 Trk 相关疾病的药物，本发明提供了一种化合物，该化合物具有选择性 Trk 抑制活性，可持续抑制 NGF 血管高渗透性，且无药物相互作用，此外，该化合物对游离碱的溶解性和可吸收性极佳。本发明的化合物具有选择性Trk-抑制活性，可持续抑制NGF血管高渗透性，且无药物相互作用，对游离碱的溶解性和吸收性极佳，因此可作为预防和/或治疗Trk相关疾病的药物。